A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. [electronic resource]
Producer: 20150331Description: 343-52 p. digitalISSN:- 1432-0843
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bevacizumab
- Biomarkers, Tumor -- metabolism
- Dose-Response Relationship, Drug
- Female
- Humans
- Male
- Middle Aged
- Neoplasms -- drug therapy
- Neovascularization, Pathologic -- drug therapy
- Paxillin -- metabolism
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.